Berkeley Newswire

Berkeley Newswire

Comprehensive Real-Time News Feed for Berkeley, CA.

Results 1 - 20 of 27 for "u:americanbankingnews.com" in Berkeley, CA

  1. Local Bestselling Author's Second Thriller to Debut at National...Read the original story w/Photo

    May 24, 2016 | AmericanBankingNews.com

    Roaring Brook Productions-bestselling author, award-winning songwriter, Thornton Cline will debut his second mystery-thriller novel, " A Travesty of Justice " , "The Amazing Incredible Shrinking Violin" zoomed all the way up to number one on the Amazon books list for children's music books in February of last year. "Bare-knuckled and breakneck.

    Comment?

  2. XOMA Corp (XOMA) Stock Rating Upgraded by Zacks Investment ResearchRead the original story w/Photo

    May 12, 2016 | AmericanBankingNews.com

    The firm currently has a $0.75 target price on the stock. Zacks Investment Research 's target price indicates a potential upside of 7.14% from the company's current price.

    Comment?

  3. Zacks Investment Research Upgrades XOMA Corp (XOMA) to BuyRead the original story w/Photo

    May 12, 2016 | AmericanBankingNews.com

    The brokerage currently has a $0.75 price objective on the stock. Zacks Investment Research 's price target would suggest a potential upside of 7.14% from the company's previous close.

    Comment?

  4. Analysts' Updated EPS Estimates for May, 12th (ADDYY, AVXL,...Read the original story w/Photo

    May 12, 2016 | AmericanBankingNews.com

    The analysts wrote, "We believe pSivida, a leader in eye drug delivery technology, is making significant progress with regulatory advancement of its eye drug, Medidur, which has already completed one of two planned Phase III studies. In particular, PSDV is on track to file for regulatory approval of Medidur in the EU by year-end.

    Comment?

  5. XOMA Corp (XOMA) Upgraded to Buy by Zacks Investment ResearchRead the original story w/Photo

    Apr 28, 2016 | AmericanBankingNews.com

    The firm currently has a $1.00 price target on the stock. Zacks Investment Research 's target price would suggest a potential upside of 10.28% from the stock's previous close.

    Comment?

  6. XOMA Corp (XOMA) Lowered to "Hold" at Zacks Investment ResearchRead the original story w/Photo

    Apr 26, 2016 | AmericanBankingNews.com

    According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1? with potential for the treatment of the inflammatory cause of multiple diseases.

    Comment?

  7. Research Analysts' Weekly Ratings Changes for XOMA CorpRead the original story w/Photo

    Mar 17, 2016 | AmericanBankingNews.com

    According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1? with potential for the treatment of the inflammatory cause of multiple diseases.

    Comment?

  8. Equities Research Analysts' Updated EPS Estimates for March,...Read the original story w/Photo

    Mar 16, 2016 | AmericanBankingNews.com

    The firm currently has C$11.00 price target on the stock, down from their previous price target of C$11.50. had its market perform rating reiterated by analysts at Leerink Swann.

    Comment?

  9. XOMA Corp (XOMA) Upgraded to Hold by Zacks Investment ResearchRead the original story w/Photo

    Mar 8, 2016 | AmericanBankingNews.com

    According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1? with potential for the treatment of the inflammatory cause of multiple diseases.

    Comment?

  10. Investment Analysts' Weekly Ratings Changes for XOMA CorpRead the original story w/Photo

    Dec 14, 2015 | AmericanBankingNews.com

    According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1? with potential for the treatment of the inflammatory cause of multiple diseases.

    Comment?

  11. XOMA Corp (XOMA) - Analysts' Weekly Ratings ChangesRead the original story w/Photo

    Dec 3, 2015 | AmericanBankingNews.com

    Several brokerages have updated their recommendations and price targets on shares of XOMA Corp in the last few weeks: 12/2/2015 - XOMA Corp was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases.

    Comment?

  12. XOMA Corp (XOMA) Downgraded by Zacks Investment Research to HoldRead the original story w/Photo

    Dec 2, 2015 | AmericanBankingNews.com

    According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1? with potential for the treatment of the inflammatory cause of multiple diseases.

    Comment?

  13. XOMA Corp (XOMA) Lowered to Hold at Zacks Investment ResearchRead the original story w/Photo

    Dec 2, 2015 | AmericanBankingNews.com

    According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1? with potential for the treatment of the inflammatory cause of multiple diseases.

    Comment?

  14. Weekly Analysts' Ratings Updates for XOMA CorpRead the original story w/Photo

    Nov 23, 2015 | AmericanBankingNews.com

    They now have a $1.50 price target on the stock. According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases.

    Comment?

  15. XOMA Corp Lifted to Buy at Zacks Investment ResearchRead the original story w/Photo

    Nov 23, 2015 | AmericanBankingNews.com

    The brokerage currently has a $1.50 target price on the stock. Zacks Investment Research 's price target points to a potential upside of 8.70% from the stock's previous close.

    Comment?

  16. Analysts' Weekly Ratings Changes for XOMA CorpRead the original story w/Photo

    Oct 8, 2015 | AmericanBankingNews.com

    According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1? with potential for the treatment of the inflammatory cause of multiple diseases.

    Comment?

  17. XOMA Corp Rating Lowered to Hold at ZacksRead the original story w/Photo

    Oct 7, 2015 | AmericanBankingNews.com

    According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1? with potential for the treatment of the inflammatory cause of multiple diseases.

    Comment?

  18. Research Analysts' Weekly Ratings Changes for XOMA CorpRead the original story w/Photo

    Sep 30, 2015 | AmericanBankingNews.com

    They now have a $0.75 price target on the stock. According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases.

    Comment?

  19. XOMA Corp Upgraded at ZacksRead the original story w/Photo

    Sep 28, 2015 | AmericanBankingNews.com

    The firm currently has a $0.75 price target on the stock. Zacks 's target price would suggest a potential downside of 2.60% from the company's current price.

    Comment?

  20. Recent Analysts' Ratings Changes for XOMA CorpRead the original story w/Photo

    Sep 22, 2015 | AmericanBankingNews.com

    According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1? with potential for the treatment of the inflammatory cause of multiple diseases.

    Comment?

Berkeley Job Listings
View or post Berkeley job listings on Topix.
Berkeley Real Estate
News, listings, and foreclosures in Berkeley from Topix.
Berkeley Mortgages
Find mortgage rates in Berkeley on Topix.